BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Company Registration Number:
14158063 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2024

Period of accounts

Start date: 1 July 2023

End date: 31 December 2024

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Directors' report period ended 31 December 2024

The directors present their report with the financial statements of the company for the period ended 31 December 2024

Principal activities of the company

Investment holding company



Directors

The directors shown below have held office during the whole of the period from
1 July 2023 to 31 December 2024

Christopher Bond
Paul O'Neill


Secretary NSM Services Limited

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
22 September 2025

And signed on behalf of the board by:
Name: Paul O'Neill
Status: Director

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Profit And Loss Account

for the Period Ended 31 December 2024

18 months to 31 December 2024 13 months to 30 June 2023


£

£
Other operating income: 23,864
Operating profit(or loss): 23,864
Interest payable and similar charges: ( 11,631 ) ( 1,341 )
Profit(or loss) before tax: 12,233 (1,341)
Profit(or loss) for the financial year: 12,233 (1,341)

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Balance sheet

As at 31 December 2024

Notes 18 months to 31 December 2024 13 months to 30 June 2023


£

£
Fixed assets
Intangible assets: 3 459,023 459,023
Total fixed assets: 459,023 459,023
Creditors: amounts falling due within one year: 4 ( 448,130 ) ( 460,363 )
Net current assets (liabilities): (448,130) (460,363)
Total assets less current liabilities: 10,893 ( 1,340)
Total net assets (liabilities): 10,893 (1,340)
Capital and reserves
Called up share capital: 1 1
Profit and loss account: 10,892 (1,341 )
Total Shareholders' funds: 10,893 (1,340)

The notes form part of these financial statements

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Balance sheet statements

For the year ending 31 December 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 22 September 2025
and signed on behalf of the board by:

Name: Paul O'Neill
Status: Director

The notes form part of these financial statements

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Intangible fixed assets amortisation policy

    Intangible assets comprises of intellectual property that is held for its investment potential, it is included in the balance sheet at cost. Consideration will be given for annual impairment reviews and carried out if deemed appropriate and economically viable.

    Other accounting policies

    Income and expenditure - Income and expenses are recognised in these financial statements on an accruals basis. Going concern - The directors have considered the financial position of the company and since it receives financial support from the ultimate beneficial owner to continue in operational existence for the foreseeable future it is considered appropriate to present these financial statements on a going concern basis. Foreign Currencies - The financial statements have been prepared in Sterling, the reporting currency of the Company. Assets and liabilities in other currencies are translated into Sterling at the rate of exchange ruling at the balance sheet date whilst transactions in other currencies are translated into Sterling at the rate of exchange ruling at the date of the transaction. Gains or losses on currency exchange are recognised in the profit and loss account. Taxation - In response to The Income Tax (Substance Requirements) (Guernsey) (Amendment) Ordinance, 2018 ("the ordinance"), the Directors have reviewed the Company’s affairs in accordance with the prescribed requirements of Economic Substance and found that for the period ended 31 December 2024 the Company was inside scope of the Ordinance having held intellectual property. The company is subject to UK income tax at a rate of 19% on the tax-adjusted income, and UK capital gains tax at a rate of 19% on the tax-adjusted gains arising on disposal of, UK-situs property.

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 2. Employees

    18 months to 31 December 2024 13 months to 30 June 2023
    Average number of employees during the period 0 0

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

3. Intangible assets

Goodwill Other Total
Cost £ £ £
At 1 July 2023 459,023 459,023
Additions
Disposals
Revaluations
Transfers
At 31 December 2024 459,023 459,023
Amortisation
At 1 July 2023 0 0
Charge for year
On disposals
Other adjustments
At 31 December 2024 0 0
Net book value
At 31 December 2024 459,023 459,023
At 30 June 2023 459,023 459,023

BIOCRYPTOLOGY HOLDINGS (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

4. Creditors: amounts falling due within one year note

18 months to 31 December 2024 13 months to 30 June 2023
£ £
Other creditors 448,130 460,363
Total 448,130 460,363